Hot Shots NM LLC

Hot Shots NM LLC, operating as Hot Shots Nuclear Medicine LLC Division and doing business as Midwest Positron Technology, is a for-profit limited liability company based in Davenport, Iowa, that manufactures and distributes radiopharmaceuticals for nuclear medicine diagnostic imaging to the Department of Veterans Affairs as a prime contractor on full-and-open, non-set-aside delivery orders and indefinite delivery contracts. The company is a wholly owned subsidiary of Pharmalogic Holdings Corp., a for-profit parent entity based in Boca Raton, Florida.

Hot Shots NM LLC specializes in the production and distribution of F-18 fluorodeoxyglucose (F-18 FDG), F-18 sodium fluoride, and non-PET radiopharmaceutical unit doses used for positron emission tomography (PET) scans and other nuclear medicine diagnostic imaging modalities. Work is classified under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC 6505 (Drugs and Biologicals), representing 28 of the company's 34 recent prime awards. All work is performed at the vendor's Davenport, Iowa radiopharmacy, which maintains NRC licensure, state-licensed radiopharmaceutical personnel, and the capability to deliver routine orders within one hour and STAT emergency orders within one hour, available 365 days annually, in compliance with NRC, DOT, and FDA regulations.

The company's customer footprint is entirely within the Veterans Affairs system. Three Veterans Integrated Service Networks (VISNs) account for 100% of awards: VISN 23 anchors the relationship with 24 awards valued at $4.7 million combined potential value, followed by VISN 10 with 8 awards worth $2.6 million, and VISN 12 with 2 awards valued at $730 thousand. Hot Shots NM LLC holds four active single-award indefinite delivery contracts with the VA: one with VISN 23 carrying a $741,888 ceiling through December 14, 2029; one with VISN 23 carrying an $87,320 ceiling through May 14, 2027; one with VISN 10 carrying a $584,161 ceiling through September 30, 2028; and one with VISN 10 carrying a $584,794 ceiling (completed September 30, 2025). Representative recent delivery orders include a $180,000 order from VISN 23 for F-18 FDG doses (December 2025), a $186,763 order from VISN 10 for radiopharmaceuticals (October 2025), and a $588,525 order from VISN 10 for radiopharmaceuticals (October 2024).

Award activity has moderated in recent years — six awards in 2022, declining to three in both 2023 and 2024, with four in 2025 and two in 2026 through mid-May. Three awards with combined potential value of $454 thousand reach ultimate completion within the next twenty-four months, representing recompete exposure. The company serves exclusively as a prime contractor with no identified subcontractors across its federal footprint. Combined potential value across all recent awards totals $8.1 million, with $3.5 million obligated to date (43% of potential value).